13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
43 檔
1.6%
The Q1 2024 SEC filing reveals that Alphabet Inc. held a total portfolio value of $99.1B, covering 43 public equity positions.
During Q1 2024, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including GTLB, CRWD, DXCM) accounted for 1.6% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GTLB | Gitlab Inc-cl A | Stock-Tech | 22.64% | -1.39% | +268.61% | |
| 2 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 10.91% | — | -33.33% | |
| 3 | DXCM | Dexcom Inc | Stock-Healthcare | 9.88% | — | -51.36% | |
| 4 | ARM | Arm Holdings Plc-adr | Stock-Tech | 9.75% | -6.69% | — | |
| 5 | FRSH | Freshworks Inc-cl A | Stock-Other | 8.94% | -3.07% | +205.70% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.80% | -7.41% | — | |
| 7 | ✓ | Verve Therapeutics Inc | Stock-Other | 6.52% | — | — | |
| 8 | PATH | Uipath Inc - Class A | Stock-Tech | 6.34% | -1.86% | — | |
| 9 | PRME | Prime Medicine Inc | Stock-Other | 4.19% | -1.38% | +26.98% | |
| 10 | SNOW | Snowflake Inc | Stock-Tech | 3.44% | — | — | |
| 11 | PL | Planet Labs Pbc | Stock-Industrials | 3.24% | -23.35% | — | |
| 12 | SANA | Sana Biotechnology Inc | Stock-Other | 1.12% | -0.19% | — | |
| 13 | IVVD | Invivyd Inc | Stock-Other | 0.80% | — | -20.31% | |
| 14 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.52% | — | — | |
| 15 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.52% | -0.36% | — | |
| 16 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.42% | -0.18% | — | |
| 17 | VERA | Vera Therapeutics Inc | Stock-Other | 0.41% | -0.23% | -20.00% | |
| 18 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.41% | -0.27% | — | |
| 19 | ✓ | Desktop Metal Inc Class A Comm | Stock-Other | 0.39% | — | — | |
| 20 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 21 | ILMN | Illumina Inc | Stock-Healthcare | 0.29% | — | — | |
| 22 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.29% | -0.13% | -70.41% | |
| 23 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.25% | — | — | |
| 24 | GUTS | Fractyl Health Inc | Stock-Other | 0.20% | — | — | |
| 25 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 26 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.19% | -0.02% | EXIT | |
| 27 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.18% | -0.02% | — | |
| 28 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.14% | — | — | |
| 29 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 30 | ✓ | Stock-Other | 0.12% | — | — | ||
| 31 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.07% | — | — | |
| 32 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.07% | — | — | |
| 33 | EXK | Exact Sciences CORP | Stock-Materials | 0.06% | — | — | |
| 34 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.06% | -0.05% | — | |
| 35 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.06% | — | — | |
| 36 | ALEC | Alector Inc | Stock-Other | 0.04% | — | — | |
| 37 | HYPR | Hyperfine Inc | Stock-Other | 0.04% | -0.02% | — | |
| 38 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.01% | — | — | |
| 39 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.01% | — | — | |
| 40 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — | |
| 41 | MOND | Mondee Holdings Inc | Stock-Other | — | — | — | |
| 42 | HLTHQ | Cue Health Inc | Stock-Other | — | — | — | |
| 43 | NVTA1EUR | Invitae CORP | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 43 disclosed positions in Q1 2024.
During Q1 2024, Alphabet Inc.'s top holdings by market value included GTLB (22.6%)、CRWD (10.9%)、DXCM (9.9%). The largest single position, GTLB, represented 22.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2024, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.